Doxorubicin (DOX) is an effective chemotherapeutic with known toxic effects over the liver, kidneys and most importantly the heart. DOX effects, such as oxidative stress induction, topoisomerase II poisoning and activation of pro-inflammatory pathways are a double-edged sword. While enhancing the antitumoral activity of this agent, these mechanisms also contribute to tissue damage which limits its use. To build upon previous research that evaluated circulating biomarkers of DOX-induced cardiac toxicity, this study offers additional perspectives on structural effects on tissues along with a short literature review of DOX use. Article history: Received 3 April 2025; Revised 1 April 2026; Accepted 2 June 2026; Available online 25 June 2026.